Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

What cancer patients actually know regarding medical cannabis? A cross-sectional survey with a critical analysis of the current attitudes.

Cortellini A, Porzio G, Cofini V, Necozione S, Giusti R, Marchetti P, Aloe Spiriti MA, Costanzi A, Peris F, Ravoni G, Spinelli G, Ficorella C, Verna L.

J Oncol Pharm Pract. 2019 May 1:1078155219843161. doi: 10.1177/1078155219843161. [Epub ahead of print]

PMID:
31042135
2.

Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice.

Cortellini A, Cannita K, Parisi A, Lanfiuti Baldi P, Venditti O, D'Orazio C, Dal Mas A, Calvisi G, Giordano AV, Vicentini V, Vicentini R, Felicioni L, Marchetti A, Buttitta F, Russo A, Ficorella C.

Onco Targets Ther. 2019 Mar 25;12:2159-2170. doi: 10.2147/OTT.S194745. eCollection 2019.

3.

Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges.

Leonetti A, Facchinetti F, Minari R, Cortellini A, Rolfo CD, Giovannetti E, Tiseo M.

Cell Oncol (Dordr). 2019 Apr 9. doi: 10.1007/s13402-019-00441-3. [Epub ahead of print] Review.

PMID:
30968324
4.

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.

Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M, Bersanelli M, Bordi P, Santini D, Giusti R, Grassadonia A, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Porzio G, Cannita K, Ficorella C, Buti S.

Clin Lung Cancer. 2019 Feb 21. pii: S1525-7304(19)30025-7. doi: 10.1016/j.cllc.2019.02.006. [Epub ahead of print]

PMID:
30885550
5.

Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis.

Parisi A, Cortellini A, Cannita K, Bersanelli M, Ficorella C.

Case Rep Oncol Med. 2019 Feb 10;2019:3452762. doi: 10.1155/2019/3452762. eCollection 2019.

6.

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.

Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, Giusti R, Tiseo M, Michiara M, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, De Giglio A, Iacono D, Gelibter A, Occhipinti MA, Parisi A, Porzio G, Fargnoli MC, Ascierto PA, Ficorella C, Natoli C.

J Immunother Cancer. 2019 Feb 27;7(1):57. doi: 10.1186/s40425-019-0527-y.

7.

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.

Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M, Bersanelli M, Michiara M, Grassadonia A, Brocco D, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Sabbatini R, Bracarda S, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, Iacono D, Migliorino MR, Rossi A, Porzio G, Cannita K, Ciciarelli V, Fargnoli MC, Ascierto PA, Ficorella C.

Oncologist. 2019 Feb 22. pii: theoncologist.2018-0618. doi: 10.1634/theoncologist.2018-0618. [Epub ahead of print]

PMID:
30796151
8.

Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma.

Bersanelli M, Gnetti L, Varotti E, Ampollini L, Carbognani P, Leonardi F, Rusca M, Campanini N, Ziglioli F, Dadomo CI, Pilato FP, Cortellini A, Rapacchi E, Caruso G, Silini EM, Maestroni U, Buti S.

Immunotherapy. 2019 Jan;11(1):21-35. doi: 10.2217/imt-2018-0097.

9.

Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation.

Napoleoni L, Cortellini A, Cannita K, Parisi A, Dal Mas A, Calvisi G, Venditti O, Baldi PL, Cocciolone V, Ricci A, Ficorella C.

Bioengineering (Basel). 2019 Jan 22;6(1). pii: E11. doi: 10.3390/bioengineering6010011.

10.

Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A "hypothesis-generator" preliminary report.

Cortellini A, Verna L, Porzio G, Bozzetti F, Palumbo P, Masciocchi C, Cannita K, Parisi A, Brocco D, Tinari N, Ficorella C.

Thorac Cancer. 2019 Feb;10(2):347-351. doi: 10.1111/1759-7714.12965. Epub 2019 Jan 2.

11.

The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A 'hypothesis-generator' study from clinical practice.

Cortellini A, Cocciolone V, Irelli A, Pavese F, Sidoni T, Parisi A, Lanfiuti Baldi P, Venditti O, D'Orazio C, Bonfili P, Franzese P, Zugaro L, Verna L, Porzio G, Santini D, Cannita K, Ficorella C.

Oncol Lett. 2018 Dec;16(6):7195-7203. doi: 10.3892/ol.2018.9561. Epub 2018 Oct 10.

12.

Family history of cancer and DNA damage response genes: Two sides of the same coin?

Cortellini A, Bersanelli M, Ficorella C, Buti S.

Thorac Cancer. 2019 Feb;10(2):401. doi: 10.1111/1759-7714.12926. Epub 2018 Dec 8. No abstract available.

13.

Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab.

Cortellini A, Napoleoni L, Cimini N, Parisi A, Pavese F, DʼOrazio C, Verna L, Porzio G, Ficorella C.

J Clin Neuromuscul Dis. 2018 Dec;20(2):99-100. doi: 10.1097/CND.0000000000000220. No abstract available.

PMID:
30439756
14.

"Palliative" or "Supportive": Is It Just a Matter of Word?

Porzio G, Cortellini A, D'Orazio C, Ficorella C, Verna L.

J Palliat Med. 2018 Nov;21(11):1546. doi: 10.1089/jpm.2018.0290. No abstract available.

PMID:
30383511
15.

INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study.

Bersanelli M, Giannarelli D, Castrignanò P, Fornarini G, Panni S, Mazzoni F, Tiseo M, Rossetti S, Gambale E, Rossi E, Papa A, Cortellini A, Lolli C, Ratta R, Michiara M, Milella M, De Luca E, Sorarù M, Mucciarini C, Atzori F, Banna GL, La Torre L, Vitale MG, Massari F, Rebuzzi SE, Facchini G, Schinzari G, Tomao S, Bui S, Vaccaro V, Procopio G, De Giorgi U, Santoni M, Ficorella C, Sabbatini R, Maestri A, Natoli C, De Tursi M, Di Maio M, Rapacchi E, Pireddu A, Sava T, Lipari H, Comito F, Verzoni E, Leonardi F, Buti S.

Immunotherapy. 2018 Oct;10(14):1229-1239. doi: 10.2217/imt-2018-0080.

PMID:
30326787
16.

Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy.

Cortellini A, Palumbo P, Porzio G, Verna L, Giordano AV, Masciocchi C, Parisi A, Cannita K, Ficorella C, Bozzetti F.

Thorac Cancer. 2018 Dec;9(12):1623-1630. doi: 10.1111/1759-7714.12870. Epub 2018 Sep 27.

17.

Where are we with treatment options after first line in small cell lung cancer?-report of two opposite cases treated with CAPTEM regimen and possible perspectives.

Cortellini A, Dal Mas A, Cannita K, Collina G, Parisi A, Pavese F, Porzio G, Verna L, Ficorella C.

J Thorac Dis. 2018 Jul;10(7):E520-E525. doi: 10.21037/jtd.2018.06.44. No abstract available.

18.

Timed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen.

Cortellini A, Cannita K, Parisi A, Venditti O, Lanfiuti Baldi P, De Berardis B, Vicentini R, Vicentini V, Verna L, Porzio G, Ficorella C.

Oncol Rep. 2018 Aug;40(2):803-812. doi: 10.3892/or.2018.6475. Epub 2018 Jun 6.

PMID:
29901103
19.

The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study.

Cortellini A, Porzio G, Masel EK, Berghoff AS, Knotzer B, Parisi A, Pavese F, Ficorella C, Verna L.

Palliat Support Care. 2019 Feb;17(1):82-86. doi: 10.1017/S1478951518000238. Epub 2018 May 24.

PMID:
29792235
20.

Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome.

Cortellini A, Parisi A, Fargnoli MC, Cannita K, Irelli A, Porzio G, Martinazzo C, Ficorella C.

Case Rep Oncol Med. 2018 Mar 8;2018:2783917. doi: 10.1155/2018/2783917. eCollection 2018.

Supplemental Content

Loading ...
Support Center